These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30633134)

  • 1. Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care.
    Tasillo A; Eftekhari Yazdi G; Nolen S; Schillie S; Vellozzi C; Epstein R; Randall L; Salomon JA; Linas BP
    Obstet Gynecol; 2019 Feb; 133(2):289-300. PubMed ID: 30633134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal Hepatitis B Antibody Screening and Vaccination in Pregnancy: A Cost-Effectiveness Analysis.
    Prabhu M; Susich MK; Packer CH; Hersch AR; Riley LE; Caughey AB
    Obstet Gynecol; 2022 Mar; 139(3):357-367. PubMed ID: 35115449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
    Eckman MH; Ward JW; Sherman KE
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
    Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
    Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare value of implementing hepatitis C screening in the adult general population in Spain.
    Buti M; Domínguez-Hernández R; Casado MÁ; Sabater E; Esteban R
    PLoS One; 2018; 13(11):e0208036. PubMed ID: 30485377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine screening for hepatitis C in pregnancy is cost-effective in a large urban population in Ireland: a retrospective study.
    McCormick CA; Domegan L; Carty PG; Drew R; McAuliffe FM; O'Donohoe O; White N; Garvey P; O'Grady M; De Gascun CF; McCormick PA
    BJOG; 2022 Jan; 129(2):322-327. PubMed ID: 34706147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States.
    Tatar M; Keeshin SW; Mailliard M; Wilson FA
    JAMA Netw Open; 2020 Sep; 3(9):e2015756. PubMed ID: 32880650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men.
    Linas BP; Wong AY; Schackman BR; Kim AY; Freedberg KA
    Clin Infect Dis; 2012 Jul; 55(2):279-90. PubMed ID: 22491339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
    Chaillon A; Rand EB; Reau N; Martin NK
    Clin Infect Dis; 2019 Nov; 69(11):1888-1895. PubMed ID: 30689769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine hepatitis C virus screening in pregnancy: a cost-effectiveness analysis.
    Plunkett BA; Grobman WA
    Am J Obstet Gynecol; 2005 Apr; 192(4):1153-61. PubMed ID: 15846195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?
    Urbanus AT; van Keep M; Matser AA; Rozenbaum MH; Weegink CJ; van den Hoek A; Prins M; Postma MJ
    PLoS One; 2013; 8(8):e70319. PubMed ID: 23950920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug users.
    Cipriano LE; Zaric GS; Holodniy M; Bendavid E; Owens DK; Brandeau ML
    PLoS One; 2012; 7(9):e45176. PubMed ID: 23028828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons.
    He T; Li K; Roberts MS; Spaulding AC; Ayer T; Grefenstette JJ; Chhatwal J
    Ann Intern Med; 2016 Jan; 164(2):84-92. PubMed ID: 26595252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England.
    Williams J; Miners A; Harris R; Mandal S; Simmons R; Ireland G; Hickman M; Gore C; Vickerman P
    Value Health; 2019 Nov; 22(11):1248-1256. PubMed ID: 31708061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.
    Kim HL; Kim KA; Choi GH; Jang ES; Ki M; Choi HY; Jeong SH
    Clin Mol Hepatol; 2022 Jan; 28(1):91-104. PubMed ID: 34736311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Microsimulation Study of the Cost-Effectiveness of Hepatitis C Virus Screening Frequencies in Hemodialysis Centers.
    Epstein RL; Pramanick T; Baptiste D; Buzzee B; Reese PP; Linas BP; Sawinski D
    J Am Soc Nephrol; 2023 Feb; 34(2):205-219. PubMed ID: 36735375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis.
    Lai JC; Kahn JG; Tavakol M; Peters MG; Roberts JP
    Am J Transplant; 2013 Oct; 13(10):2611-8. PubMed ID: 24034208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness and budget impact analysis of facility-based screening and treatment of hepatitis C in Punjab state of India.
    Chugh Y; Premkumar M; Grover GS; Dhiman RK; Teerawattananon Y; Prinja S
    BMJ Open; 2021 Feb; 11(2):e042280. PubMed ID: 33589457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
    Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.